Biblio

Author Title [ Type

] Year

Filters: Author is Nannya, Yasuhito [Clear All Filters]

Journal Article

Nannya Y, Viswabandya A, Lu P. Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia. Blood Cell Ther. 2022;5(Spec Edition):S25-S33.

Shingai N, Mizumaki H, Najima Y, Yamada Y, Tran DCao, Haraguchi K, Toya T, Okuyama Y, Doki N, Nannya Y, et al. Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria. Front Immunol. 2023;14:1329403.

Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016.

Shiozawa Y, Fujita S, Nannya Y, Ogawa S, Nomura N, Kiguchi T, Sezaki N, Kudo H, Toyama T. First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants. Int J Hematol. 2024.

Sato-Otsubo A, Nannya Y, Kashiwase K, Onizuka M, Azuma F, Akatsuka Y, Ogino Y, Satake M, Sanada M, Chiba S, et al. Genome-wide surveillance of mismatched alleles for graft versus host disease in stem cell transplantation. Blood. 2015.

Kanamori T, Sanada M, Ri M, Ueno H, Nishijima D, Yasuda T, Tachita T, Narita T, Kusumoto S, Inagaki A, et al. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. Br J Haematol. 2020.

Yamamoto K, Goyama S, Asada S, Fujino T, Yonezawa T, Sato N, Takeda R, Tsuchiya A, Fukuyama T, Tanaka Y, et al. A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Rep. 2021;36(8):109576.

Shrestha R, Sakata-Yanagimoto M, Maie K, Oshima M, Ishihara M, Suehara Y, Fukumoto K, Nakajima-Takagi Y, Matsui H, Kato T, et al. Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. Blood Adv. 2020;4(5):845-854.

Asimomitis G, Deslauriers AG, Kotini AG, Bernard E, Esposito D, Olszewska M, Spyrou N, Ossa JEsteban Ar, Mortera-Blanco T, Koche RPatrick, et al. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Adv. 2022.

Kubota H, Ueno H, Tasaka K, Isobe T, Saida S, Kato I, Umeda K, Hiwatari M, Hasegawa D, Imamura T, et al. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia. Blood Adv. 2023.

Boddu PC, Gupta AK, Roy R, Avalos BDe La Peñ, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, et al. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Mol Cell. 2024.

Toratani K, Watanabe M, Kanda J, Oka T, Hyuga M, Arai Y, Iwasaki M, Sakurada M, Nannya Y, Ogawa S, et al. Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations. Int J Hematol. 2023.